Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Parasitic organism or component thereof or substance...
Reexamination Certificate
2011-01-11
2011-01-11
Graser, Jennifer E (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Parasitic organism or component thereof or substance...
C424S185100, C424S184100, C424S193100, C424S265100, C424S192100, C530S350000
Reexamination Certificate
active
07867503
ABSTRACT:
A method for treatment or prevention ofToxoplasma gondiiinfections pharmaceutical composition comprising an antigen fragments ofToxoplasma gondiiin the form of a chimeric fusion product or a nucleotide sequence coding for the chimeric fusion product and a method of using the chimeric fusion product or nucleotide sequence coding therefor.
REFERENCES:
patent: 4877726 (1989-10-01), Suzuki
patent: 5215917 (1993-06-01), De Araujo
patent: 5633139 (1997-05-01), Prince
patent: 5665542 (1997-09-01), Prince
patent: 5686575 (1997-11-01), Prince
patent: 5962654 (1999-10-01), Duncombe
patent: 5976553 (1999-11-01), Kim
patent: 6221619 (2001-04-01), Maine
patent: 6265176 (2001-07-01), Lin
patent: 6392014 (2002-05-01), Cesbron
patent: 1450087 (2003-10-01), None
patent: 0 082 745 (1983-06-01), None
patent: 0 301 961 (1989-02-01), None
patent: 0 391 319 (1990-10-01), None
patent: 0 431 541 (1991-06-01), None
patent: 0 724 016 (1996-07-01), None
patent: 0 751 147 (1997-01-01), None
patent: 0 710 724 (1998-05-01), None
patent: 2226468 (1974-11-01), None
patent: 2702491 (1994-09-01), None
patent: 1196817 (1988-11-01), None
patent: 54044016 (1979-04-01), None
patent: 11225783 (1999-08-01), None
patent: 2000300278 (2000-10-01), None
patent: 533376 (1976-10-01), None
patent: 89/05658 (1989-06-01), None
patent: 89/08700 (1989-09-01), None
patent: 89/12683 (1989-12-01), None
patent: 92/01067 (1992-01-01), None
patent: 92/02624 (1992-02-01), None
patent: 92/11366 (1992-07-01), None
patent: 94/17813 (1994-08-01), None
patent: 96/02654 (1996-02-01), None
patent: 97/27300 (1997-07-01), None
patent: 98/20734 (1998-05-01), None
patent: 99/32633 (1999-07-01), None
patent: 99/57295 (1999-11-01), None
patent: 99/61906 (1999-12-01), None
patent: 99/66043 (1999-12-01), None
patent: 01/63283 (2001-03-01), None
patent: 01/64243 (2001-09-01), None
patent: 03/080839 (2003-02-01), None
patent: 03/080839 (2003-10-01), None
patent: 2004/031358 (2004-04-01), None
Greenspan et al (Nature Biotechnology 7: 936-937, 1999).
Chothia et al (The Embo Journal, 1986, 5/4:823-26).
Murphy et al. Pediatr. Infect. Dis. J. 1989. 8: S66-S68.
Yamanaka et al (J. Pediatrics. 1993. 122(2): 212-218).
Yang, Chung-Dar et al. “Protective immunity againstToxoplasma gondiiin mice induced by chimeric protein rSAG1/2”. Parasitology Research, vol. 92, No. 1, Jan. 2004, pp. 58-64.
Beghetto, Elisa et al. “A Combination of Antigenic Regions ofToxoplasma gondiiMicroneme Proteins Induces Protective Immunity against Oral Infection with Parasite Cysts”. Journal of Infectious Diseases, 191, Feb. 2005, pp. 637-645.
Beghetto, Elisa et al. “Identification of a human immunodominant B-cell epitope within the GRA1 antigen ofToxoplasma gondiiby phage display of cDNA libraries”. International Journal of Parasitology, Pergamon Press, GB, vol. 31, No. 14, Dec. 2001, pp. 1659-1668.
Hiszczynska—Sawicka Elzbieta et al. “High yield expression and single-step purification ofToxoplasma gondiiSAG1, GRA1, and GRA7 antigens inEscherichia coli”. Protein Expression and Purification, vol. 27, No. 1, Jan. 2003, pp. 150-157.
PCT International Search Report for PCT/EP2006/001760 filed on Feb. 27, 2006 in the name of Kenton SRL.
PCT Written Opinion for PCT/EP2006/001760 filed on Feb. 27, 2006 in the name of Kenton SRL.
PCT International Preliminary Report on Patentability for PCT/EP2006/001760 filed on Feb. 27, 2006 in the name of Kenton SRL.
Beaman et al., “Principles and Practice of Infectious Diseases”, 4th Ed., Churchill Livingstone Inc., New York, 1995, pp. 2455-2475.
Beghetto et al., “Molecular dissection of the human B-cell response againstToxoplasma gondiiinfection by lambda display of cDNA libraries”, International Journal for Parasitology, 2003, 33:163-173.
Bermudes et al., “Cloning of a eDNA encoding the dense granule protein GRA3 fromToxoplasma gondii”, Mol. Biochem. Parasitol., 1994, 68:247-257.
Bonhomme et al., “Quantitative Immunolocalization of a P29 Protein (GRA7), a New Antigen ofToxoplasma gondii”, J. Histochem. Cytochem., 1998, 46:1411-1421.
Burg et al., “Molecular Analysis of the Gene Encoding the Major Surface Antigen ofToxoplasma gondii”, J. Immunol., 1988, 141:3584-3591.
Cesbron-Delauw, et al., “Molecular characterization of a 23-kilodalton major antigen secreted byToxoplasma gondii”, 1989 P.N.A.S. USA 86, 7537-41.
Cohen, J.S., “Designing antisense oligonucleotides as pharmaceutical agents”, Trends in Pharm. Sci., 10,435, 1989.
Cooney et al., “Site-Specific Oligonucleotide Binding Represses Transcription of the Humanc-mycGene in Vitro”, Science 241, 456, 1988).
Dervan et al., “Second Structural Motif for Recognition ofDNA by Oligonucleotide-Directed Triple-Helix Fonnation”, Science 251, 1360, 1991.
Garcia-Réguet et al., “The microneme protein MIC3 ofToxoplasma gondiiis a secretory adhesin that binds to both the surface of the host cells and the surface of the parasite”, Cellular Microbiol., 2000, 2:353-364.
Harning et al., “RecombinantToxoplasma gondiiSurface Antigen 1 (P30) Expressed inEscherichia coliIs Recognized by Human Toxoplasma-Specific Immunoglobulin M (IgM) and IgG Antibodies”, Clinical and Diagnostic Laboratory Immunology, May 1996, 355-357.
Hauser, William E. et al., “Augmentation of NK Activity by Soluble and Particulate Fractions ofToxoplasma gondii”, The Journal of Immunology, vol. 131, No. 1, Jul. 1983, pp. 458-463.
Jacobs et al., “Identification and heterologous expression of a new dense granule protein (GRA7) fromToxoplasma gondii”, Mol. Biochem. Parasitol. 91, 1998, 237-49.
Lecordier al., “Characterization of a dense granule antigen ofToxoplasma gondii(GRA6) associated to the network of the parasitophorolls vacuole”, Mol. Biochem. Parasitol. 1995, 70, 85-94.
Lee et al., “Complexes formed by (Pyrimidine)n (purine)n DNAs on lowering the pH are three-stranded”, Nucleic Acids Res 6,3073, 1979.
Luft, B.J., Remington J.S., “Toxoplasmic Encephalitis in AIDS”, 1992, Clin. Infect. Dis. 15, 211-22.
McCabe and Remington, “Toxoplasmosis; The Time Has Come”, N. Engl. J. Med. 1988, 318-313-5.
Meinkoth et al. “Hybridization of Nucleic Acids Immobilized on Solid Supports”,Analytical Biochemistry 138,267-284, 1984.
Mevelec et al., “Molecular cloning of GRA4, aToxoplasma gondiidense granule protein, recognized by mucosal IgA antibodies”, Mol. Biochem. Parasitol. 56, 1992, 227-38.
Minenkova et al., “Identification of Tumor-Associated Antigens by Screening Phage-Displayed Human cDNA Libraries With Sera From Tumor Patients”, International Journal of Cancer, 2003, 106:534-44.
Okano, et al., Myelin Basic Protein Gene and the Function of Antisense RNA in Its Repression in Myelin-Deficient Mutant Mouse: J. Neurochem 56,560,1991.
Parmley et al., “Expression, Characterization, and Serologic Reactivity of Recombinant Surface Antigen P22 ofToxoplasma gondii”, 1992, J. Clin. Microbiol. 30, 1127-33.
Prince et al., “Cloning of cDNAs encoding a 28 kilodalton antigen ofToxoplasma gondii”, Mol. Biochem. Parasitol., 34, 1989, 3-14.
Rabenau et al., “TgM2AP participates inToxoplasma gondiiinvasion of host cells and is tightly associated with the adhesive protein TgMIC2”, Mol. Microbiol., 2001, 41:537-547.
Remington JS et al., “Infectious Diseases of the Fetus and Newborn Infant”, W.B. Saunders, Philadelphia, PA, 140-267, 1995.
Robben et al. “Selection and Identification of Dense Granule Antigen GRA3 byToxoplasma gondiiWhole Genome Phage Display”, 2002, J. Biol. Chem. 277, 17544-47.
Wan et al, “Molecular characterisation of an expressed sequence tag locus ofToxoplasma gondiiencoding the micronemal protein MIC2”, Mol. Biochem.Parasitol., 1997, 84:203-214.
Final Rejection issued by USPTO for U.S. Appl. No. 11/885,951 dated Sep. 30, 2009.
Non-Final Rejectio
Beghetto Elisa
Gargano Nicola
Spadoni Andrea
Graser Jennifer E
Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
Steinfl & Bruno LLP
LandOfFree
Chimeric recombinant antigens of Toxoplasma gondii does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric recombinant antigens of Toxoplasma gondii, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric recombinant antigens of Toxoplasma gondii will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2652341